Ax­el Hoos, the keep­er of the on­col­o­gy flame at Glax­o­SmithK­line, steps away for his next chal­lenge at tiny Scor­pi­on

Ax­el Hoos has long kept the flame alive at Glax­o­SmithK­line’s on­col­o­gy di­vi­sion, en­dur­ing lean days af­ter the British phar­ma ditched its late-stage pipeline to No­var­tis and de­cid­ed to re­build anew. Now, watch­ing the pipeline he helped re­mold fi­nal­ly bear fruit, Hoos is ready for a new chal­lenge — and it will come at a tiny biotech at the fron­tier of “pre­ci­sion med­i­cine 2.0.”

Hoos will jump ship af­ter a nine-year stint at GSK to helm Scor­pi­on Ther­a­peu­tics, a stealthy biotech work­ing on iden­ti­fy­ing and tar­get­ing “un­drug­gable” tar­gets in on­col­o­gy. He will pick up the man­tle in Au­gust, mark­ing his long-await­ed re­turn to biotech and first go at the CEO role.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER